The evaluation of the efficacy of Alflutop in the complex treatment of patients with chronic lower back pain (the observational study ZEITNOT)

Close metadata

OBJECTIVE

To analyze the effect of Alflutop on neuroinflammation in patients with chronic lower back pain (CBP).

MATERIAL AND METHODS

Forty-one patients with a verified CBP diagnosis were enrolled in the study. Alflutop was used for treating CBP, 1 ml once/day, for 20 days. Treatment efficacy was monitored using the Visual Analogue Scale (VAS), DN4 test; the Roland-Morris questionnaire; the index of pain activity in the lumbar spine; and the level of tumor necrosis factor-α (TNF-α) in blood plasma. There were three visits in total: screening (visit 0), treatment start (visit 1, 0—3 days after screening) and visit 2 (3 months later (±7 days) from the start of treatment).

RESULTS

Before the start of therapy, in some patients (group 1, n=14 (34.1%) the TNF-α concentration in the blood plasma was below the detectable level (less than 4.0 pg/ml), while in group 2 (n=27 (659%)), the expression of TNF-α in peripheral blood was observed at the level of 6.3 [4.9; 7.4] pg/ml. Patients in group 2 significantly (p<0.05) differed from patients in group 1 by the greater number of CBP exacerbations over the last year as well as by the results of testing on DN4 (higher values) and SBI (greater discomfort). In group 2, a significant relationship was found between the TNF-α level in blood plasma and the number of exacerbations as well as between the TNF-α level and the number of DN4 points. At visit 2, patients in group 2 had a significant (p<0.05) decrease in pain intensity according to VAS, an improvement in the quality of life according to the Roland-Morris questionnaire, a decrease in the severity of the neuropathic component of pain according to DN4 test as well as subjective condition improvement associated with the activity of pain in the lumbar spine. A significant relationship was found between the level of TNF-α and the number of DN4 points after treatment and the period of active observation.

CONCLUSIONS

In the majority of CBP patients, the high relapse rate and neuropathic nature of pain may be associated with persistent neuroinflammation due to TNF-α synthesis. Alflutop inhibits the TNF-α expression substantially, which significantly correlates with a decrease in the neuropathic pain syndrome component according to the DN4 questionnaire. The use of Alflutop can be considered as an effective method of treating patients with CBP, which has an impact on the process of neuroinflammation as one of the leading causes of changes in the pain nature and its chronicity.

Keywords:

chronic lower back pain

neuroinflammation

tumor necrosis factor -α

Alflutop

Authors:

Samartcev I.N.

Kirov Military Medical Academy

SPIN RSCI: 9857-4986
Scopus AuthorID: 57218542945
ORCID: 0000-0002-7659-9756

Zhivolupov S.A.

Kirov Military Medical Academy

Barantsevich E.R.

Pavlov First Saint Petersburg State Medical University

ORCID: 0000-0003-3804-3877

Danilov A.B.

Sechenov First Moscow State Medical University (Sechenov University)

Received:

16.12.2020

Accepted:

12.01.2021

List of references:

Ma K, Zhuang Z, Wang L, Liu X, Lu L, Yang X, Lu Y, Fu Z, Song T, Huang D, Liu H, Huang Y, Peng B, Liu Y. The Chinese Association for the Study of Pain (CASP): Consensus on the Assessment and Management of Chronic Nonspecific Low Back Pain. Pain Res Manag. 2019:8957847. https://doi.org/10.1155/2019/8957847
Borenstein D. Low back pain and lumbar spinal stenosis. In: Hochberg MC, Silman A, Smolen J, et al. (eds.), Rheumatology (3rd edn.), Mosby, St. Louis, Mo; 2003;583-613.
Melloh M, Röder C, Elfering A, Theis JC, Müller U, Staub LP, Aghayev E, Zweig T, Barz T, Kohlmann T, Wieser S, Jüni P, Zwahlen M. Differences across health care systems in outcome and cost-utility of surgical and conservative treatment of chronic low back pain: a study protocol. BMC Musculoskelet Disord. 2008;9:81. https://doi.org/10.1186/1471-2474-9-81
Vorobieva OV. Chronic back pain: from pathogenetic concepts to therapeutic strategies. Medical Council. 2017;(17):36-42. (In Russ.). https://doi.org/10.21518/2079-701X-2017-17-36-42
Baron A, Binder N, Attal R, Casale A, Dickenson H, Treede R-D. Neuropathic low back pain in clinical practice. European Journal of Pain. 2016;20(6): 861-873. https://doi.org/10.1002/ejp.838
Balagué F, Mannion AF, Pellisé F, Cedraschi C. Non-specific low back pain. Lancet. 2012;379:482-491. https://doi.org/10.1016/S0140-6736(11)60610-7
DePalma MJ, Ketchum JM, Saullo T. What is the source of chronic low back pain and does age play a role? Pain Medicine.2011;12:224-233. https://doi.org/10.1111/j.1526-4637.2010.01045.x
https://www.iasp-pain.org/PublicationsNews/NewsDetail.aspx?ItemNumber=6862
Bakker EW, Verhagen AP, van Trijffel E, Lucas C, Koes BW. Spinal mechanical load as a risk factor for low back pain: a systematic review of prospective cohort studies. Spine. 2009;34(8):281-93. https://doi.org/10.1097/BRS.0b013e318195b257
Zhivolupov SA, Samartsev IN, Syroezhkin FA. Modern concept of neuroplasticity (theoretical aspects and practical significance). S.S. Korsakov Journal of Neurology and Psychiatry. 2013;113(10):102-108. (In Russ.).
Reichling DB, Levine JD. Critical role of nociceptor plasticity in chronic pain. Trends Neurosci. 2009;32:611-618. https://doi.org/10.1016/j.tins.2009.07.007
Woolf CJ, Salter MW. Neuronal plasticity: increasing the gain in pain. Science. 2000;288:1765-1769. https://doi.org/10.1126/science.288.5472.1765
Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology. 2018;129(2):343-366. https://doi.org/10.1097/ALN.0000000000002130
Jensen MP, Karoly P, Braver S. The measurement of clinical pain intensity: a comparison of six methods. Pain. 1986;27:117-126. https://doi.org/10.1016/0304-3959(86)90228-9
Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain. 2005;114(1-2):29-36. https://doi.org/10.1016/j.pain.2004.12.010
Roland M, Morris R. A study of the natural history of back pain. Part I: development of a reliable and sensitive measure of disability in low-back pain. Spine. 1976;8(2):141-144. https://doi.org/10.1097/00007632-198303000-00004
Patrick DL, Deyo RA, Atlas SJ, Singer DE, Chapin A, Keller RB. Assessing health-related quality of life in patients with sciatica. Spine. 1995;20:1899-1908. https://doi.org/10.1097/00007632-199509000-00011
Yunkerov VI, Grigoryev SG. Matematiko-statisticheskaya obrabotka dannykh meditsinskikh issledovanij. SPb: VMedA; 2005. (In Russ.).
Wang H, Schiltenwolf M, Buchner M. The role of TNF-alpha in patients with chronic low back pain: a prospective, comparative longitudinal study. Clin J Pain. 2008;24:273-278. https://doi.org/10.1097/AJP.0b013e31816111d3
De Queiroz BZ, Pereira DS, Lopes RA, Lopes RA, Felício DC, Silva JP, de Britto Rosa NM, Dias JMD, Dias RC, Lustosa LP, Pereira LSM. Association Between the Plasma Levels of Mediators of Inflammation With Pain and Disability in the Elderly With Acute Low Back Pain: Data From the Back Complaints in the Elders (BACE) — Brazil Study. Spine. 2016;41(3):197-203. https://doi.org/10.1097/BRS.0000000000001214
Gebhardt K, Brenner H, Sturmer T, Raum E, Richter W, Schiltenwolf M, Buchner M. The course of high-sensitive C-reactive protein in correlation with pain and clinical function in patients with acute lumbosciatic pain and chronic low back pain — a 6 months prospective longitudinal study. Eur J Pain. 2006;10(8):711-719. https://doi.org/10.1016/j.ejpain.2005.11.005
Leung L, Cahill CM. TNF-alpha and neuropathic pain — a review. J Neuroinflamation. 2010;7(1):27. https://doi.org/10.1186/1742-2094-7-27
Empl M, Renaud S, Erne B, Fuhr P, Straube A, Schaeren-Wiemers N, Steck AJ. TNF-alpha expression in painful and nonpainful neuropathies. Neurology. 2001;56(10):1371-1377. https://doi.org/10.1212/wnl.56.10.1371
Caroyer J, Manto M, Steinfeld S. Severe sensory neuronopathy responsive to infliximab in primary Sjögren’s syndrome. Neurology. 2002;59(7):113-114. https://doi.org/10.1212/wnl.59.7.1113
Karppinen J, Korhonen T, Malmivaara A, Paimela L, Kyllönen E, Lindgren K-A, Rantanen P, Tervonen O, Niinimäki J, Seitsalo S, Hurri H. Tumor Necrosis Factor-α Monoclonal Antibody, Infliximab, Used to Manage Severe Sciatica. Spine. 2003;28(8):750-753. https://doi.org/10.1097/01.brs.0000058944.38900.ce
Danilov AB, Zharkova TR, Akhmetdzhanova LT. Analgesic properties of Alflutop in treatment of chronic back pain. Nevrologiya i revmatologiya. 2010;2:26-29. (In Russ.).
Levin OS, Olyunin DYu, Golubeva LV. The efficacy of Alflutop in chronic vertebrogenic lumboischialgia according to a double-blind, placebo-controlled study. Nauchno-prakticheskaya revmatologiya. 2004;42(4):80-84. (In Russ.). https://cyberleninka.ru/article/n/effektivnost-alflutopa-pri-hronicheskoy-vertebrogennoy-lyumboishialgii-po-dannym-dvoynogo-slepogo-platsebo-kontroliruemogo

Close metadata